Cargando…

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells

Epidermal growth factor receptor (EGFR), member of the human epidermal growth factor receptor (HER) family, plays a critical role in regulating multiple cellular processes including proliferation, differentiation, cell migration and cell survival. Deregulation of the EGFR signaling has been found to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Presutti, Dario, Santini, Simonetta, Cardinali, Beatrice, Papoff, Giuliana, Lalli, Cristiana, Samperna, Simone, Fustaino, Valentina, Giannini, Giuseppe, Ruberti, Giovina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651538/ https://www.ncbi.nlm.nih.gov/pubmed/26580964 http://dx.doi.org/10.1371/journal.pone.0143333

Ejemplares similares

CASP4 gene silencing in epithelial cancer cells leads to impairment of cell migration, cell-matrix adhesion and tissue invasion
por: Papoff, Giuliana, et al.
Publicado: (2018)

Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines
por: Fustaino, Valentina, et al.
Publicado: (2017)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Tis21-gene therapy inhibits medulloblastoma growth in a murine allograft model
por: Presutti, Dario, et al.
Publicado: (2018)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
por: Urbanska, Edyta M., et al.
Publicado: (2023)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
por: Seki, Nobuhiko, et al.
Publicado: (2019)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
por: Peters, T. L., et al.
Publicado: (2021)

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
por: Demuth, Christina, et al.
Publicado: (2017)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells
por: Clement, Michelle Simone, et al.
Publicado: (2020)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications
por: Feldt, Susan L., et al.
Publicado: (2023)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
por: Liam, Chong Kin, et al.
Publicado: (2023)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)

MET-8 Chemotherapy alone for brain metastases from small cell lung cancer -comparison with EGFR-TKI-
por: Iuchi, Toshihiko, et al.
Publicado: (2021)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Cai, Boning, et al.
Publicado: (2021)

HGF-independent Potentiation of EGFR Action by c-Met
por: Dulak, Austin M., et al.
Publicado: (2011)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells
por: Jakobsen, K R, et al.
Publicado: (2017)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
por: KATO, HIROAKI, et al.
Publicado: (2013)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
por: Liu, Li, et al.
Publicado: (2021)

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
por: Sun, Dantong, et al.
Publicado: (2022)

Involvement of lipid rafts in adhesion-induced activation of Met and EGFR
por: Lu, Ying-Che, et al.
Publicado: (2011)

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
por: Ju, Lixia, et al.
Publicado: (2013)

Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
por: Gao, Hong-Fei, et al.
Publicado: (2016)

MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
por: Qin, Kang, et al.
Publicado: (2023)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
por: Raghav, Kanwal, et al.
Publicado: (2016)

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
por: Li, Jing-Wen, et al.
Publicado: (2019)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
por: Miyoshi, Seigo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_btvte192pt6qtls6bh868kfjvh